Are We There Yet? Strategies to Employ JAK Inhibitors in T2T for RA
| Overview / Abstract: |
Are you effectively employing treat-to-target strategies into your daily practice? Data from the Corrona RA registry tell a different story: a large number of patients with RA still had moderate or high levels of disease activity after 6 and 12 months of csDMARD and/or bDMARD therapy, with no acceleration of treatment. Dr. Allan Gibofsky, Co-Director, Clinic for Inflammatory Arthritis and Biologic Therapy at the Hospital for Special Surgery and New York Presbyterian Hospital in New York explains how to select the right target for each patient, how often to assess whether the target has been achieved, and how to optimize selection of each subsequent therapy, including when to introduce JAK inhibitors. |
|
Expiration |
Jan 20, 2022 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
1.0 |
|
Accreditation |
ACCME |
|
Is This Activity Certified for "Live" Credit? |
YES |
|
Presenters / Authors / Faculty |
Allan Gibofsky, MD, JD, MACR, FACP, FCLM |
|
Activity Specialities / Related Topics |
Rheumatology / Arthritis, Rehabilitation / Therapy, Primary Care, Pharmacology, Pain Management, Internal Medicine, Geriatrics / LTC, Family Medicine |
|
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Gilead Sciences, Inc. |
|
Keywords / Search Terms |
ACHL JAKis, JAK/STAT pathway, JAK-naïve, shared decision-making, treat-to-target, treating-to-target, T2T, ACR paradigm, inflammatory disease, signaling pathway, autoimmune disorders, janus kinase, immune-mediated inflammatory diseases, JAK1, JAK2, JAK3, JAK/STAT signaling, cytokine-rheumatoid arthritis, chronic inflammation, novel rheumatology drugs, JAKi, tofacitinib, baricitinib, filgotinib, upadacitinib, JAK inhibitor, RA |
|